0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Human Health Effects Nanoplastics Sign in to save

Micro-nanoplastics and Parkinson’s disease: evidence and perspectives

npj Parkinson s Disease 2026
Lu Lin, Jin Li, Si Zhu, Zhiling Zhang, Zhigang Li, Pingyi Xu, Wenyuan Guo

Summary

Researchers reviewed growing evidence linking micro- and nanoplastic exposure to Parkinson's disease, a degenerative brain condition. Lab studies suggest these particles may accelerate disease by promoting the misfolding of a key brain protein (alpha-synuclein), triggering inflammation, and damaging mitochondria — though large-scale human studies are still needed to establish causation and define safe exposure thresholds.

With the intensification of global plastic pollution, the potential threats posed by micro- and nanoplastics (MPs/NPs) to human health have become a major concern. MPs/NPs enter the organism through ingestion, inhalation, and skin contact, subsequently accumulating in multiple organs-particularly the brain. Increasing experimental and epidemiological evidence implicates MPs/NPs in the development of Parkinson's disease (PD). Preclinical research models indicate that MPs/NPs may accelerate both the initiation and progression of PD by facilitating α-synuclein misfolding and aggregation, triggering neuroinflammatory cascades, elevating oxidative stress, and impairing mitochondrial function. To further investigate the causal role of MPs/NPs in PD, upcoming studies should emphasize well-designed, large-scale prospective cohorts to assess individual exposure to plastic-related pollutants, elucidate the pathways of MPs/NPs into the central nervous system, establish safety thresholds for their neurotoxicity, explore the correlation between exposure levels and central nervous system accumulation, clarify the temporal relationship between MPs/NPs accumulation and PD pathology and symptom onset, and identify the neuropathological mechanisms triggered by relevant concentrations of MPs/NPs. Such data will be instrumental in informing preventive and potentially interventional strategies, while offering actionable insights into the interaction between MPs/NPs and PD.

Share this paper